The field of lung cancer management is rapidly evolving because of the introduction of newer treatment modalities like stereotactic radiotherapy. The purpose of this focused issue on Stereotactic Radiotherapy and Lung Cancer is to discuss current paradigms and controversies on relevant and practical topics related to the use of lung SABR that face the modern oncologist in daily treatment decisions.
Stereotactic ablative radiation therapy for operable early-stage lung cancer—considerations and controversies
Certainty versus practicality: when is histologic proof needed prior to stereotactic ablative radiotherapy for solitary pulmonary nodules?
Is radiotherapy the missing link to enhancing the outcomes in non-small cell lung cancer patients treated with immunotherapy?
More are coming……